Nanobiotix (NASDAQ:NBTX) Shares Up 5.8% – Should You Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) traded up 5.8% on Friday . The stock traded as high as $21.12 and last traded at $21.23. 212 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 38,057 shares. The stock had previously closed at $20.06.

Wall Street Analyst Weigh In

NBTX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.00.

Nanobiotix Price Performance

The business has a 50 day moving average price of $21.55 and a 200 day moving average price of $16.08.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.